|
|
name  click to compare prices |
» Shop local, ethical and at the best price on Ethishop  |
|
| |
|
| shareholder | country | % | source |
|
year | business source |
| 2006 | Teva is the world's eighteenth-largest pharmaceutical group. | Les Echos |
| 2006 | Teva manufactures 25 billion pills per year, 5000 different drugs in 40 factories. | Les Echos |
| 2004 | World's largest generic drug maker. | Les Echos |
|
| country | address & contact : production type incentive source |
 China | Tianjin Hualida Biotechnology Co., Ltd : Company |
 Mexico | Lemery Desarrollo y Control, S.A. de C.V : Company |
| Mexico | Lemery, S.A. de C.V : Company |
| Mexico | Sicor de México, S.A. de C.V. : Company |
|
| year name | photo position; compensation source |
|
| year | employees <> | social impact : country source |
|
| year | employees <> | social impact : country source |
|
| year | financial misdemeanor | sales | income | | | source |
| 2005 |
Sued by the State of California for defrauding the state's $34 billion Medi-Cal program by inflating prices. "We're going to drag these drug companies into courts of law because they've been gouging the public," California Attorney General Bill Lockyer said at a news conference. For example, Medi-Cal paid $804.70 US for a bottle of the hypertension drug Atenolol. Providers such as doctors, clinics and pharmacists paid $33.85 US. As a result, providers reimbursed by Medi-Cal for Atenolol pocketed $770.85 US. The windfalls gave doctors, pharmacies and other providers an incentive to prescribe such drugs, which resulted in even more sales by drug makers, Lockyer said. |
| 5.25 | 1.07 | | | billion US$ | Canadian Press |
| 2004 |
| 4.8 | 0.33 | | | billion US$ | Company |
| 2003 |
| 3.28 | 0.69 | | | billion US$ | Company |
| 2002 |
| 2.52 | 0.41 | | | billion US$ | Company |
| 2001 |
| 2.08 | 0.28 | | | billion US$ | Company |
| 2000 |
| 1.75 | 0.15 | | | billion US$ | Company |
| 1999 |
| 1.28 | 0.12 | | | billion US$ | Company |
| 1998 |
| 1.12 | 0.07 | | | billion US$ | Company |
|
| year | financial misdemeanor | sales | income | assets | buyback | source |
|
|
|
Contribute
&sa=OK&client=pub-2642534665785160&forid=1&channel=6290198667&ie=ISO-8859-1&oe=ISO-8859-1&flav=0002&sig=NuXwWEvBGZspbgPc&cof=GALT%3A%23CEA7FF%3BGL%3A1%3BDIV%3A%234A4A4A%3BVLC%3AFF6600%3BAH%3Acenter%3BBGC%3A4A4A4A%3BLBGC%3A4A4A4A%3BALC%3AFFB42D%3BLC%3AFFB42D%3BT%3AFFFFFF%3BGFNT%3AE8DBEF%3BGIMP%3ACEA7FF%3BLH%3A26%3BLW%3A304%3BL%3Ahttp%3A%2F%2Fwww.transnationale.org%2Fimages%2Ftrans2.gif%3BS%3Ahttp%3A%2F%2Fwww.transnationale.org%3BFORID%3A11&hl=en){kind=link}
&sa=OK&client=pub-2642534665785160&forid=1&channel=6290198667&ie=ISO-8859-1&oe=ISO-8859-1&flav=0002&sig=NuXwWEvBGZspbgPc&cof=GALT%3A%23CEA7FF%3BGL%3A1%3BDIV%3A%234A4A4A%3BVLC%3AFF6600%3BAH%3Acenter%3BBGC%3A4A4A4A%3BLBGC%3A4A4A4A%3BALC%3AFFB42D%3BLC%3AFFB42D%3BT%3AFFFFFF%3BGFNT%3AE8DBEF%3BGIMP%3ACEA7FF%3BLH%3A26%3BLW%3A304%3BL%3Ahttp%3A%2F%2Fwww.transnationale.org%2Fimages%2Ftrans2.gif%3BS%3Ahttp%3A%2F%2Fwww.transnationale.org%3BFORID%3A11&hl=en){kind=link}